Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
Vor Bio (Nasdaq: VOR) has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in global clinical development. Dr. Zuraw most recently served as Chief Development Officer at RemeGen, where she led the successful development of telitacicept across multiple autoimmune indications, securing regulatory approvals in China for SLE, generalized MG, and RA treatments.
At RemeGen, Dr. Zuraw managed clinical trial design, regulatory strategy, and achieved Fast Track, Breakthrough Therapy, and Orphan Drug designations. Her previous experience includes senior roles at Janssen, Teva, Akebia, Biogen, and Covance, where she contributed to multiple NDA and BLA submissions and the FDA approval of Guselkumab for psoriatic arthritis.
This strategic appointment aims to strengthen Vor Bio's execution of late-stage programs and global development initiatives, particularly in the U.S. market.
Vor Bio (Nasdaq: VOR) ha nominato la Dott.ssa Qing Zuraw come Chief Development Officer, portando con sé oltre 25 anni di esperienza nello sviluppo clinico a livello globale. La Dott.ssa Zuraw ha ricoperto recentemente il ruolo di Chief Development Officer presso RemeGen, dove ha guidato con successo lo sviluppo di telitacicept per diverse indicazioni autoimmuni, ottenendo le approvazioni regolatorie in Cina per i trattamenti di SLE, miastenia grave generalizzata e artrite reumatoide.
In RemeGen, la Dott.ssa Zuraw ha gestito la progettazione degli studi clinici, la strategia regolatoria e ha ottenuto le designazioni Fast Track, Breakthrough Therapy e Orphan Drug. La sua esperienza precedente include ruoli senior presso Janssen, Teva, Akebia, Biogen e Covance, dove ha contribuito a numerose sottomissioni NDA e BLA e all'approvazione FDA di Guselkumab per l'artrite psoriasica.
Questa nomina strategica mira a rafforzare l'esecuzione dei programmi in fase avanzata e le iniziative di sviluppo globale di Vor Bio, in particolare nel mercato statunitense.
Vor Bio (Nasdaq: VOR) ha designado a la Dra. Qing Zuraw como Chief Development Officer, aportando más de 25 años de experiencia en desarrollo clínico global. La Dra. Zuraw se desempeñó recientemente como Chief Development Officer en RemeGen, donde lideró con éxito el desarrollo de telitacicept para múltiples indicaciones autoinmunes, obteniendo aprobaciones regulatorias en China para los tratamientos de SLE, miastenia grave generalizada y artritis reumatoide.
En RemeGen, la Dra. Zuraw gestionó el diseño de ensayos clínicos, la estrategia regulatoria y logró las designaciones Fast Track, Breakthrough Therapy y Orphan Drug. Su experiencia previa incluye cargos senior en Janssen, Teva, Akebia, Biogen y Covance, donde contribuyó a múltiples presentaciones de NDA y BLA y a la aprobación por la FDA de Guselkumab para artritis psoriásica.
Este nombramiento estratégico busca fortalecer la ejecución de los programas en etapas avanzadas y las iniciativas de desarrollo global de Vor Bio, especialmente en el mercado de EE.UU.
Vor Bio (나스닥: VOR)는 Dr. Qing Zuraw를 최고개발책임자(Chief Development Officer)로 임명했으며, 글로벌 임상 개발 분야에서 25년 이상의 경험을 보유하고 있습니다. Zuraw 박사는 최근 RemeGen에서 최고개발책임자로 근무하며 다수의 자가면역질환 적응증에 걸친 텔리타시셉트 개발을 성공적으로 이끌었고, 중국에서 SLE, 전신 중증 근무력증, 류마티스 관절염 치료제에 대한 규제 승인도 획득했습니다.
RemeGen에서 Zuraw 박사는 임상시험 설계, 규제 전략을 관리했으며, Fast Track, Breakthrough Therapy, 희귀약 지정도 받았습니다. 이전에는 Janssen, Teva, Akebia, Biogen, Covance에서 고위직을 역임하며 다수의 NDA 및 BLA 제출과 FDA의 건선성 관절염 치료제 Guselkumab 승인에 기여했습니다.
이번 전략적 임명은 Vor Bio가 후기 단계 프로그램과 글로벌 개발 이니셔티브, 특히 미국 시장에서의 실행력을 강화하는 데 목적이 있습니다.
Vor Bio (Nasdaq : VOR) a nommé Dr Qing Zuraw au poste de Chief Development Officer, apportant plus de 25 ans d'expérience en développement clinique mondial. Dr Zuraw a récemment occupé le poste de Chief Development Officer chez RemeGen, où elle a dirigé avec succès le développement de telitacicept pour plusieurs indications auto-immunes, obtenant les approbations réglementaires en Chine pour les traitements du LES, de la myasthénie généralisée et de la polyarthrite rhumatoïde.
Chez RemeGen, Dr Zuraw a géré la conception des essais cliniques, la stratégie réglementaire et a obtenu les désignations Fast Track, Breakthrough Therapy et Orphan Drug. Son expérience antérieure inclut des postes de direction chez Janssen, Teva, Akebia, Biogen et Covance, où elle a contribué à plusieurs soumissions de NDA et BLA ainsi qu'à l'approbation par la FDA de Guselkumab pour l'arthrite psoriasique.
Cette nomination stratégique vise à renforcer l'exécution des programmes en phase avancée et les initiatives de développement global de Vor Bio, notamment sur le marché américain.
Vor Bio (Nasdaq: VOR) hat Dr. Qing Zuraw als Chief Development Officer berufen, die über 25 Jahre Erfahrung in der globalen klinischen Entwicklung mitbringt. Dr. Zuraw war zuletzt Chief Development Officer bei RemeGen, wo sie die erfolgreiche Entwicklung von Telitacicept für mehrere autoimmune Indikationen leitete und regulatorische Zulassungen in China für SLE, generalisierte Myasthenia gravis und RA-Behandlungen erhielt.
Bei RemeGen verantwortete Dr. Zuraw das Studiendesign, die regulatorische Strategie und erzielte Fast Track-, Breakthrough Therapy- und Orphan Drug-Designationen. Zuvor hatte sie leitende Positionen bei Janssen, Teva, Akebia, Biogen und Covance inne, wo sie zu mehreren NDA- und BLA-Einreichungen sowie zur FDA-Zulassung von Guselkumab bei Psoriasis-Arthritis beitrug.
Diese strategische Ernennung soll die Umsetzung von Vor Bios späten Entwicklungsprogrammen und globalen Initiativen, insbesondere auf dem US-Markt, stärken.
- Appointment of highly experienced executive with 25+ years in clinical development
- New CDO has proven track record with multiple regulatory approvals in China
- Previous success in securing Fast Track, Breakthrough Therapy, and Orphan Drug designations
- Strong expertise in global regulatory interactions (FDA, EMA, CDE)
- None.
- Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development focus and execution of late-stage programs
CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately.
Dr. Zuraw joins Vor Bio with over 25 years of experience leading complex global and U.S. clinical development programs across autoimmune, inflammatory, and immunologic diseases. Most recently, she served as Chief Development Officer and Head of Global Clinical Development for Autoimmune Diseases at RemeGen Co., Ltd., where she was one of the key leaders of successful development and execution of clinical trials for telitacicept across four key indications—systemic lupus erythematosus (SLE), Sjögren’s syndrome, myasthenia gravis (MG), and rheumatoid arthritis (RA)—culminating in regulatory approvals in China for the treatment of SLE, generalized MG and RA.
At RemeGen, Dr. Zuraw built and led a cross-functional global team that managed all aspects of telitacicept development, including clinical trial design, regulatory strategy, site engagement, and execution. She played a central role in regulatory interactions with the U.S. Food & Drug Administration, European Medicines Agency, and China’s Center for Drug Evaluation, achieving Fast Track, Breakthrough Therapy, and Orphan Drug designations for telitacicept across multiple indications.
“We are delighted to welcome Qing to Vor Bio at a critical time for the company,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. “Her deep and diverse clinical development expertise across autoimmune and immunological diseases and with telitacicept will be invaluable as we execute on our late-stage programs. Qing’s ability to lead high-performing clinical organizations will be instrumental as we drive forward our global development programs, particularly in the U.S.”
Dr. Zuraw has also previously held senior leadership roles at Janssen Research & Development, Teva Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Biogen Inc., and Covance, Inc., where she led global clinical development programs across rheumatology, nephrology, respiratory, and immunology. She played a key role in the U.S. FDA approval of Guselkumab for psoriatic arthritis and contributed to multiple NDA and BLA submissions across therapeutic areas. Throughout her career, she has built and led high-performing teams to execute complex trials from early development through post-marketing.
“Vor Bio is uniquely positioned to become a leader in autoimmune therapeutics,” said Dr. Zuraw. “Having been intimately involved in the development of telitacicept in China from early clinical stages through to multiple approvals, I’m thrilled to join the talented team at Vor Bio to bring telitacicept to patients globally.”
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding Vor Bio’s development plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Media & Investor Contacts:
Sarah Spencer
+1 857-242-6076
investors@vorbio.com
Carl Mauch
investors@vorbio.com
FAQ
Who is the new Chief Development Officer at Vor Bio (VOR)?
What are Dr. Zuraw's major achievements at RemeGen?
What is Dr. Zuraw's previous work experience?
When did Vor Bio announce the appointment of Dr. Qing Zuraw?
What will be Dr. Zuraw's main responsibilities at Vor Bio?
